Estradiol

Estradiol

Drug monograph · NCLEX study reference
Trade names	Estrace, Climara
Therapeutic class	Estrogen replacement
Pharmacologic class	Estrogen hormone
Onset / peak / duration	Formulation dependent (daily oral, weekly or twice-weekly patch).
Half-life / level	Varies; no routine level.
Routes	PO (oral), Transdermal, Vaginal
High-alert (ISMP)	No
Black box warning	Yes (see Safety)
Antidote / reversal	None; discontinue.
Pregnancy / lactation	Contraindicated.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Estradiol (brand names Estrace, Climara) — Estrogen replacement; Estrogen hormone.

Identification

• Therapeutic class: Estrogen replacement.
• Pharmacologic class: Estrogen hormone.

Pharmacology

• Mechanism of action: Replaces estrogen to relieve menopausal symptoms and support bone.
• Onset / peak / duration: Formulation dependent (daily oral, weekly or twice-weekly patch).
• Half-life / therapeutic level: Varies; no routine level.

Clinical use

• Indications: Menopausal vasomotor symptoms, vaginal atrophy, osteoporosis prevention, hypoestrogenism.
• Usual dose, route, frequency: PO daily, transdermal patch, or vaginal forms.
• Maximum dose / adjustments: Lowest effective dose for the shortest time; add a progestin if the uterus is intact.

Safety

• Contraindications: Estrogen-dependent cancer, undiagnosed vaginal bleeding, history of venous thromboembolism or stroke, active liver disease, pregnancy.
• Black box warning: Increased risk of endometrial cancer (unopposed estrogen), cardiovascular events, breast cancer, and probable dementia (based on hormone therapy trials).
• Interactions: CYP3A4 inducers and inhibitors, thyroid hormone, smoking (raises clot risk), St. John's wort (herbal).
• Pregnancy / lactation: Contraindicated.
• High-alert: No.

Adverse effects

• Common side effects: Breast tenderness, nausea, headache, fluid retention.
• Serious effects to report: Signs of clot (leg pain, chest pain, shortness of breath, vision changes), abnormal bleeding.
• Antidote / reversal: None; discontinue.

Nursing process

• Assessment before administration: Bleeding history, clot and cancer risk, blood pressure, smoking status.
• Interventions during therapy: Use lowest effective dose; pair with a progestin when uterus is present.
• Monitor: Blood pressure, breast and pelvic exams, lipid and bleeding patterns.
• Evaluation / expected outcome: Relief of menopausal symptoms.

Patient teaching

• Patient teaching: Report leg swelling, chest pain, or vision changes; do not smoke.
• Notify provider if: Calf pain or swelling, chest pain, sudden vision or speech changes, abnormal bleeding.
• Administration tips: Rotate patch sites; take oral with food if nausea.